Cited by 627Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and ManagementCardiovascular Function and Risk Factors

Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk

Open access
Grundy, Scott M.·2012·Journal of the American College of Cardiology

Abstract

Pre-diabetes represents an elevation of plasma glucose above the normal range but below that of clinical diabetes. Pre-diabetes can be identified as either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). The latter is detected by oral glucose tolerance testing. Both IFG and IGT are risk factors for type 2 diabetes, and risk is even greater when IFG and IGT occur together. Pre-diabetes commonly associates with the metabolic syndrome. Both in turn are closely associated with obesity. The mechanisms whereby obesity predisposes to pre-diabetes and metabolic syndrome are incompletely understood but likely have a common metabolic soil. Insulin resistance is a common factor; systemic inflammation engendered by obesity may be another. Pre-diabetes has only a minor impact on microvascular disease; glucose-lowering drugs can delay conversion to diabetes, but whether in the long run the drug approach will delay development of microvascular disease is in dispute. To date, the drug approach to prevention of microvascular disease starting with pre-diabetes has not been evaluated. Pre-diabetes carries some predictive power for macrovascular disease, but most of this association appears to be mediated through the metabolic syndrome. The preferred clinical approach to cardiovascular prevention is to treat all the metabolic risk factors. For both pre-diabetes and metabolic syndrome, the desirable approach is lifestyle intervention, especially weight reduction and physical activity. When drug therapy is contemplated and when the metabolic syndrome is present, the primary consideration is prevention of cardiovascular disease. The major targets are elevations of cholesterol and blood pressure.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2011.08.080

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 83 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Grundy, S. M.
Affiliations
The University of Texas Southwestern Medical Center (US)
Corresponding author
Grundy, Scott M.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2012-02
Volume
59
Issue
7
Pages
635-643
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2078784990
Cited by
627
References
83
Citations by year
2026: 20 · 2025: 18 · 2024: 28 · 2023: 31 · 2022: 44 · 2021: 59 · 2020: 45 · 2019: 47 · 2018: 46 · 2017: 53 · 2016: 61 · 2015: 52 · 2014: 51 · 2013: 51 · 2012: 19
FWCI
7.69
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
prediabetes, metabolic syndrome, cardiovascular risk, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, obesity, insulin resistance, systemic inflammation, microangiopathy, macroangiopathy, antidiabetic drugs, lifestyle intervention, weight loss, physical activity, cholesterol, blood pressure
MeSH terms
Animals, Blood Glucose, Cardiovascular Diseases, Humans, Prediabetic State, Risk Factors, Metabolic Syndrome, Risk Reduction Behavior

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review